Bernstein Downgrades Summit Therapeutics to Underperform Following FDA Rejection of Ivonescimab
Bernstein analyst Jeffrey Walch has downgraded Summit Therapeutics (SMMT) from Market Perform to Underperform. The downgrade follows the FDA's decision to decline approval for ivonescimab, the company's lead drug candidate developed in partnership with China-based Akeso (AKESF). The move is driven by growing concerns regarding Summit's research and development capabilities following this regulatory setback. This shift reflects increased skepticism from analysts about the company's ability to navigate the clinical and regulatory pathways for its primary pipeline assets.

Tickers: $SMMT
Topics: Biotechnology FDA Rejection R&D Concerns Stock Downgrade
Read the full article at Seeking Alpha
Part of the story Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab Combination Therapy (6 articles)